PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Negative EBIT growth while TRVN is at 13.87%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-20.40%
Negative operating income growth while TRVN is at 13.87%. Joel Greenblatt would press for urgent turnaround measures.
-19.78%
Negative net income growth while TRVN stands at 10.78%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
12.20%
EPS growth under 50% of TRVN's 31.43%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
12.20%
Diluted EPS growth under 50% of TRVN's 31.43%. Michael Burry would worry about an eroding competitive position or excessive dilution.
35.62%
Share count expansion well above TRVN's 29.68%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
35.62%
Diluted share count expanding well above TRVN's 29.68%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Negative OCF growth while TRVN is at 48.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-10.88%
Negative FCF growth while TRVN is at 48.83%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-812.85%
Negative 10Y OCF/share CAGR while TRVN stands at 92.57%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.84%
5Y OCF/share CAGR is similar to TRVN's 93.02%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
86.67%
3Y OCF/share CAGR similar to TRVN's 90.31%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-1279.04%
Negative 10Y net income/share CAGR while TRVN is at 87.02%. Joel Greenblatt sees a major red flag in long-term profit erosion.
88.03%
5Y net income/share CAGR similar to TRVN's 83.98%. Walter Schloss might see both on parallel mid-term trajectories.
86.27%
3Y net income/share CAGR similar to TRVN's 85.55%. Walter Schloss would attribute it to shared growth factors or demand patterns.
1371.24%
Equity/share CAGR of 1371.24% while TRVN is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-83.09%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-60.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Negative asset growth while TRVN invests at 84.80%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-34.03%
We have a declining book value while TRVN shows 54.99%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-19.69%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.98%
R&D dropping or stable vs. TRVN's 45.40%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
58.15%
SG&A growth well above TRVN's 23.91%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.